The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

In the latest session, Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $2.54 up 1.20% from its previous closing price of $2.51. In other words, the price has increased by $1.20 from its previous closing price. On the day, 9.39 million shares were traded. ESPR stock price reached its highest trading level at $2.6156 during the session, while it also had its lowest trading level at $2.37.

Ratios:

For a deeper understanding of Esperion Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.

On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8. BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 17 ’25 when Looker Benjamin sold 1,304 shares for $1.13 per share. The transaction valued at 1,470 led to the insider holds 399,937 shares of the business.

Halladay Benjamin sold 11 shares of ESPR for $12 on Jul 17 ’25. The Chief Financial Officer now owns 474,462 shares after completing the transaction at $1.11 per share. On Jul 17 ’25, another insider, Looker Benjamin, who serves as the Officer of the company, bought 1,304 shares for $1.13 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 512122432 and an Enterprise Value of 1024238976. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91. Its current Enterprise Value per Revenue stands at 3.82 whereas that against EBITDA is -28.982.

Stock Price History:

The Beta on a monthly basis for ESPR is 0.92, which has changed by 0.45977008 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 49.54%, while the 200-Day Moving Average is calculated to be 52.61%.

Shares Statistics:

For the past three months, ESPR has traded an average of 4.86M shares per day and 7238960 over the past ten days. A total of 200.16M shares are outstanding, with a floating share count of 196.97M. Insiders hold about 2.31% of the company’s shares, while institutions hold 48.89% stake in the company. Shares short for ESPR as of 1755216000 were 22636104 with a Short Ratio of 4.65, compared to 1752537600 on 22097452. Therefore, it implies a Short% of Shares Outstanding of 22636104 and a Short% of Float of 11.2799995.

Earnings Estimates

Current recommendations for the stock of the company come from 5.0 analysts. The consensus estimate for the next quarter is $0.24, with high estimates of $0.62 and low estimates of -$0.11.

Analysts are recommending an EPS of between $0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.04, with 6.0 analysts recommending between $0.35 and -$0.28.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $78.33M this quarter.It ranges from a high estimate of $96.7M to a low estimate of $58.7M. As of the current estimate, Esperion Therapeutics Inc’s year-ago sales were $51.63MFor the next quarter, 7 analysts are estimating revenue of $146.69M. There is a high estimate of $210.2M for the next quarter, whereas the lowest estimate is $65.3M.

A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $439.4M, while the lowest revenue estimate was $236.52M, resulting in an average revenue estimate of $367.2M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $341.59M in the next fiscal year. The high estimate is $396.8M and the low estimate is $263.6M.